Page 88 - Read Online

Guerriero et al. Hepatoma Res 2019;5:6 I http://dx.doi.org/10.20517/2394-5079.2018.108 Page 21 of 22

113. Lu LC, Hsu CH, Hsu C, Cheng AL. Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges. Liver Cancer
2016;5:128-38.
114. Chen K, Zhang H, Zhang LN, Ju SQ, Qi J, et al. Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma. World J
Gastroenterol 2013;19:3143-9.
115. Ren N, Ye QH, Qin LX, Zhang BH, Liu YK, et al. Circulating DNA level is negatively associated with the long-term survival of
hepatocellular carcinoma patients. World J Gastroenterol 2006;12:3911-4.
116. Iyer P, Zekri AR, Hung CW, Schiefelbein E, Ismail K, et al. Concordance of DNA methylation pattern in plasma and tumor DNA of
Egyptian hepatocellular carcinoma patients. Exp Mol Pathol 2010;88:107-11.
117. Oussalah A, Rischer S, Bensenane M, Conroy G, Filhine-Tresarrieu P, et al. Plasma mSEPT9: A Novel Circulating Cell-free DNA-
Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. EBioMedicine 2018;30:138-47.
118. Hu N, Fan XP, Fan YC, Chen LY, Qiao CY, et al. Hypomethylated Ubiquitin-Conjugating Enzyme2 Q1 (UBE2Q1) Gene Promoter in
the Serum Is a Promising Biomarker for Hepatitis B Virus-Associated Hepatocellular Carcinoma. Tohoku J Exp Med 2017;242:93-
100.
119. Jiao J, Watt GP, Stevenson HL, Calderone TL, Fisher-Hoch SP, et al. Telomerase reverse transcriptase mutations in plasma DNA in
patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors. Hepatol Commun 2018;2:718-31.
120. Liao W, Yang H, Xu H, Wang Y, Ge P, et al. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in
hepatocellular carcinoma patients by targeted deep sequencing. Oncotarget 2016;7:40481-90.
121. Garcia-Fernandez N, Macher HC, Rubio A, Jimenez-Arriscado P, Bernal-Bellido C, et al. Detection of p53 Mutations in Circulating
DNA of Transplanted Hepatocellular Carcinoma Patients as a Biomarker of Tumor Recurrence. Adv Exp Med Biol 2016;924:25-8.
122. Xu H, Zhu X, Xu Z, Hu Y, Bo S, et al. Non-invasive Analysis of Genomic Copy Number Variation in Patients with Hepatocellular
Carcinoma by Next Generation DNA Sequencing. J Cancer 2015;6:247-53.
123. Chan KC, Jiang P, Zheng YW, Liao GJ, Sun H, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number
aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 2013;59:211-24.
124. Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting
hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012;2:e000825.
125. Zhu HT, Hasan AM, Liu RB, Zhang ZC, Zhang X, et al. Serum microRNA profiles as prognostic biomarkers for HBV-positive
hepatocellular carcinoma. Oncotarget 2016;7:45637-48.
126. Fu Y, Wei X, Tang C, Li J, Liu R, et al. Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular
carcinoma. Oncol Lett 2013;6:1811-5.
127. Sohn W, Kim J, Kang SH, Yang SR, Cho JY, et al. Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma.
Exp Mol Med 2015;47:e184.
128. Huang JT, Liu SM, Ma H, Yang Y, Zhang X, et al. Systematic Review and Meta-Analysis: Circulating miRNAs for Diagnosis of
Hepatocellular Carcinoma. J Cell Physiol 2016;231:328-35.
129. Hung CH, Hu TH, Lu SN, Kuo FY, Chen CH, et al. Circulating microRNAs as biomarkers for diagnosis of early hepatocellular
carcinoma associated with hepatitis B virus. Int J Cancer 2016;138:714-20.
130. Luo J, Chen M, Huang H, Yuan T, Zhang M, et al. Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma.
Onco Targets Ther 2013;6:577-83.
131. Fang T, Lv H, Lv G, Li T, Wang C, et al. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to
foster lung metastasis of liver cancer. Nat Commun 2018;9:191.
132. Zhang J, Lin H, Wang XY, Zhang DQ, Chen JX, et al. Predictive value of microRNA-143 in evaluating the prognosis of patients with
hepatocellular carcinoma. Cancer Biomark 2017;19:257-62.
133. Zhao Q, Sun X, Liu C, Li T, Cui J, et al. Expression of the microRNA-143/145 cluster is decreased in hepatitis B virus-associated
hepatocellular carcinoma and may serve as a biomarker for tumorigenesis in patients with chronic hepatitis B. Oncol Lett
2018;15:6115-22.
134. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin
Gastroenterol 2011;45:355-60.
135. Chen L, Chu F, Cao Y, Shao J, Wang F. Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with
hepatocellular carcinoma. Tumour Biol 2015;36:7439-47.
136. Amr KS, Ezzat WM, Elhosary YA, Hegazy AE, Fahim HH, et al. The potential role of miRNAs 21 and 199-a in early diagnosis of
hepatocellular carcinoma. Gene 2016;575:66-70.
137. Bihrer V, Waidmann O, Friedrich-Rust M, Forestier N, Susser S, et al. Serum microRNA-21 as marker for necroinflammation in
hepatitis C patients with and without hepatocellular carcinoma. PLoS One 2011;6:e26971.
138. Li F, Wang F, Zhu C, Wei Q, Zhang T, et al. miR-221 suppression through nanoparticle-based miRNA delivery system for
hepatocellular carcinoma therapy and its diagnosis as a potential biomarker. Int J Nanomedicine 2018;13:2295-307.
139. Bhattacharya S, Steele R, Shrivastava S, Chakraborty S, Di Bisceglie AM, et al. Serum miR-30e and miR-223 as novel noninvasive
biomarkers for hepatocellular carcinoma. Am J Pathol 2016;186:242-7.
140. Okajima W, Komatsu S, Ichikawa D, Miyamae M, Kawaguchi T, et al. Circulating microRNA profiles in plasma: identification of
miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function. Oncotarget 2016;7:53820-36.
141. Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a
multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol 2015;16:804-15.
142. Gui J, Tian Y, Wen X, Zhang W, Zhang P, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for
detecting liver pathologies. Clin Sci (Lond) 2011;120:183-93.
143. Chen Y, Dong X, Yu D, Wang X. Serum miR-96 is a promising biomarker for hepatocellular carcinoma in patients with chronic